Bioinfra Life Sciences Reveals Research Results on Screening Tests for High-Risk Breast Cancer Groups

[Asia Economy Reporter Hyungsoo Park] Bioinfra Life Sciences announced on the 15th that it presented the research results of X-FINDER BC, a breast cancer high-risk group screening test, at the ‘2nd AACR-KCA Joint Conference on Precision Medicine for Solid Tumors’ held for two days from the 11th to the 12th at Lotte Hotel Seoul.

The AACR-KCA Joint Conference on Precision Medicine for Solid Tumors is an academic conference jointly hosted by the American Association for Cancer Research (AACR) and the Korean Cancer Association (KCA). It is a venue where cancer researchers worldwide present the latest research results and broaden their insights on development directions.

X-FINDER BC is an in vitro diagnostic medical device that analyzes the expression levels of multiple gene markers closely related to breast cancer formation and progression in the blood and then provides a breast cancer risk score.

They disclosed research results confirming the breast cancer screening performance of a combination of multiple gene markers targeting specimens from Korean women under 50 years old with a high proportion of dense breasts. Based on their own validity analysis, they confirmed that in the under-50 age group (20?50 years), it has high performance with a sensitivity of 85%, specificity of 93%, and area under the curve (AUC) of 0.961.

For women in their 20s and 30s, breast tissue is dense, making mammography accuracy somewhat low, and since breast activity is vigorous during this period and sensitive to radiation, there is no suitable screening method. Considering the trend of increasing breast cancer incidence among women in their 20s and 30s in Korea, this is a meaningful result.

Dr. Cheolwoo Kim, founder and CTO of Bioinfra Life Sciences, said, "Mammography, generally used for breast cancer screening, shows relatively low sensitivity in women under 50 with a high proportion of dense breasts."

He added, "Although additional validation is needed with large-scale specimens providing clinical information on dense breasts, it was highly evaluated in that it showed the possibility of a screening test that can complement the sensitivity of mammography in Korean women under 50 with a high proportion of dense breasts."

Bioinfra Life Sciences is an in vitro diagnostic specialized company whose main business is discovering biomarkers for early cancer diagnosis and targeted drug delivery systems. X-FINDER BC, for breast cancer auxiliary diagnosis, is currently preparing clinical trials for approval by the Korean Ministry of Food and Drug Safety. Through joint research clinical trials with national universities and hospitals in the Middle East, where the proportion of dense breasts is relatively high, they plan to enter the Middle Eastern breast cancer screening market as well.